Mesoblast Limited

Announcements / Press Releases

2016-December-23	Mesoblast and Mallinckrodt Enter into Equity Purchase Agreement to Exclusively Negotiate Development and Commercialization of Mesoblast's Cell Therapy Products for Chronic Low Back Pain and Acute Graft Versus Host Disease (in PDF)
2016-December-9	United States Congress Legislates New Accelerated Approval Pathway for Regenerative Advanced Therapies (in PDF)
2016-December-6	MD Anderson Cancer Center and National Institutes of Health to Fund Clinical Trial Combining Two Proprietary Mesoblast Technologies for Rapid Engraftment of Stem Cell Transplants in Cancer Patients (in PDF)
2016-November-22	Results of Annual General Meeting Held 22 November 2016 (in PDF)
2016-November-22	Chairman's Address to the 2016 Annual General Meeting (in PDF)
2016-November-15	Mesoblast Provides Corporate Update and Financial Results for the First Quarter Ended September 30, 2016 (in PDF)
2016-November-14	Mesoblast Announces Successful Interim Futility Analysis in Phase 3 Trial for Acute Graft Versus Host Disease (in PDF)
2016-October-31	Appendix 4C - Quarterly Report for Entities Subject to Listing Rule 4.7B (in PDF)
2016-October-21	Notice of Annual General Meeting and Explanatory Memorandum (in PDF)
2016-October-21	Appendix 4G - Key to Disclosures Corporate Governance Council Principles and Recommendations (in PDF)
2016-October-18	Mesoblast Named 2016 Cell Therapy Company of the Year at Frost & Sullivan Asia Pacific Best Practices Awards (in PDF)
2016-October-12	Mesoblast Japan Strategy Highlighted at Australia-Japan Business Council Annual Meeting (in PDF)
2016-October-6	Phase 2 Trial Results of Mesoblast's Cell Therapy in Diabetic Kidney Disease Published (in PDF)
2016-September-1	Mesoblast Appoints Bill Burns, Former Chief Executive of Roche Pharmaceuticals, as Vice Chairman (in PDF)
2016-August-25	Preliminary Final Report (Including App 4E) (in PDF)
2016-August-25	Mesoblast Reports Financial Results and Operational Highlights for the Three Months and for the Year Ended 30 June 2016 (in PDF)
2016-August-19	Appendix 3B - New Issue Announcement, Application for Quotation of Additional Securities and Agreement (in PDF)
2016-August-17	Mesoblast Strengthens Key United States Patent Portfolio for the Treatment of Rheumatic Diseases (in PDF)
2016-August-9	Phase 2 Trial Results of Mesoblast's Cell Therapy Show Dose-Related Improvements in Biologic Refractory Rheumatoid Arthritis (in PDF)
2016-August-1	Mesoblast's Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science (in PDF)
2016-July-29	Appendix 4C - Quarterly Report for Entities Admitted on the Basis of Commitments (in PDF)
2016-July-1	Mesoblast Provides Update on Heart Failure Trial and Funding of Clinical Operations (in PDF)
2016-June-14	Mesoblast Provides Update on Global Heart Failure Program (in PDF)
2016-June-10	Extension of Voluntary Suspension (in PDF)
2016-May-20	Mesoblast Receives $6.2 Million from Australian Government for Research and Development Activities (in PDF)
2016-May-12	Form 604 - Notice of Change of Interests of Substantial Holder (in PDF)
2016-May-10	Mesoblast Reports Financial Results for Period Ended 31 March 2016 and Provides Corporate Update (in PDF)
2016-May-10	Form 6-K - Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 - Filed in the Month of May 2016 for the Period Ended March 31, 2016 (in PDF)
2016-May-9	Form 604 - Notice of Change of Interests of Substantial Holder (in PDF)
2016-May-9	Form 604 - Notice of Change of Interests of Substantial Holder (in PDF)
2016-April-28	Appendix 3B and Prospectus for Issue of Employee Options (in PDF)
2016-April-28	Appendix 4C - Quarterly Report for Entities Admitted on the Basis of Commitments (in PDF)
2016-April-19	Release of Shares from Voluntary Escrow (in PDF)
2016-April-1	Mesoblast Cell Therapy Shows Disease Modifying Effects on Knee Osteoarthritis (in PDF)
2016-March-24	Key United States Patent Granted for Cell-Based Treatment of Rheumatoid Arthritis and Other Rheumatic Conditions (in PDF)
2016-March-17	New Mesoblast Cell Targeting Technology Shows Potential to Induce Durable Reversal of Type 1 Diabetes (in PDF)
2016-February-26	Appendix 3B - New Issue Announcement, Application for Quotation of Additional Securities and Agreement (in PDF)
2016-February-24	First Allogeneic Cell Therapy Product Launched in Japan by Mesoblast Licensee (in PDF)
2016-February-22	Mesoblast's Cell Therapy Increases Survival in Children with Acute Graft Versus Host Disease (in PDF)
2016-February-17	Mesoblast Reports on First Half and Second Quarter Financial Results (in PDF)
2016-Febrary-16	Mesoblast Cell Therapy Shows Clinical Benefit in First Cohort of Patients with Biologic Refractory Rheumatoid Arthritis (in PDF)
2016-January-28	Appendix 4C - Quarterly Report for Entities Admitted on the Basis of Commitments (in PDF)
2016-January-19	Form 604 - Notice of Change of Interests of Substantial Holder (in PDF)
2016-January-11	Phase 3 Heart Failure Trial Size to be Substantially Reduced Following FDA Discussions (in PDF)
2016-January-8	Mesoblast to Present at the 34th Annual J. P. Morgan Healthcare Conference (in PDF)
2017	2017 Announcements / Press Releases
2015	2015 Announcements / Press Releases
2014	2014 Announcements / Press Releases
2013	2013 Announcements / Press Releases
2012	2012 Announcements / Press Releases
2011	2011 Announcements / Press Releases
2010	2010 Announcements / Press Releases
2009	2009 Announcements / Press Releases
2008	2008 Announcements / Press Releases
2007	2007 Announcements / Press Releases